Hrodna

This observational, prospective, multi-center study focuses on patients with chronic lymphocytic leukemia CLL in Belarus. It aims to collect real-world data on the use of acalabrutinib in routine clinical practice, addressing important knowledge gaps about its effectiveness, safety, and impact on patient quality of life. All treatment decisions are made by clinicians without study intervention. Participants in this study will be those newly prescribed acalabrutinib monotherapy, meaning they receive acalabrutinib alone without other anti-leukemic drugs around the time of starting treatment. Both treatment-nave and relapsedrefractory CLL patients are eligible. The study involves no comparator or control group and monitors patients over approximately two years with periodic data collection. During the study, researchers will track outcomes such as the time until treatment discontinuation, reasons for stopping treatment, dose changes, treatment interruptions, and any subsequent therapies. Participants are observed without altering their care, with data gathered at regular intervals to assess treatment patterns, safety, and quality of life throughout the study period.